D-0383-2021 Class II Ongoing
FDA drug recall D-0383-2021 was initiated by Hyobin LLC on Apr 6, 2021 and is designated Class II. Reason for recall: Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil. The recall status is ongoing. Affected quantity: 300 cards.
Recall details
- Product Type
- Drugs
- Report Date
- May 26, 2021
- Initiation Date
- Apr 6, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 300 cards
Product description
Triple SupremeZen Plus 3500, packaged in cardboard blisters containing one capsule per card, Distributed by Yolo Studio, Cliffside Park, NJ
Reason for recall
Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.
Distribution pattern
USA Nationwide
Code information
all lots
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0383-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026